Alchemia wins patents for generic fondaparinux
Wednesday, 25 June, 2008
Alchemia (ASX: ACL) has been granted patents for two of its family of the synthetic heparin oligosaccharides used in its fondaparinux synthesis production method.
Two of its other patent applications have been approved but not yet finalised.
The patents will grant legal protection to Alchemia's method of synthesising fondaparinux sodium up until the year 2022.
Alchemia, and its manufacturing partner Dr Reddy's, hope to go to market in 2009.
Fondaparinux is an anticoagulant medication,generally used subcutaneously daily, particularly in the treatment of deep-vain thrombosis and in those recovering from orthopaedic surgery.
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
TGA approves therapy for paediatric growth hormone deficiency
The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...
